{
  "url": "https://openlegislation.uk/eu-decision-2005-626/annex-II",
  "json_url": "https://openlegislation.uk/eu-decision-2005-626/annex-II.json",
  "legislation": "eudn/2005/626",
  "legislation_title": "Commission Decision of 23 August 2005 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2005 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2005) 333) (Only the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic) (Text with EEA relevance) (2005/626/EC)",
  "legislation_url": "https://openlegislation.uk/eu-decision-2005-626",
  "path": "annex/II",
  "kind": "annex",
  "number": "II",
  "heading": "ESSENTIAL MEDICAL USES",
  "text": "Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:\n3M Health Care (UK)\nAventis (UK)\nBespak (UK)\nBoehringer Ingelheim (DE)\nChiesi (IT)\nGlaxo Smith Kline (ES, FR, PL, UK)\nIG Sprühtechnik (DE)\nInyx Pharmaceuticals (UK)\nIVAX (IE)\nLaboratorio Aldo-Unión (ES)\nSicor (IT)\nV.A.R.I. (IT)\nValeas (IT)\nValois (FR)",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudn/2005/626/annex/II",
    "retrieved_at": "2026-11-01T15:17:49.968379+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}